Case Report of Successful Symptomatic Management of Elderly Patient with Very High-Risk MDS-Transformed AML

American Society of Hematology (ASH) recommends antileukemic therapy over best supportive care for older adults with acute myeloid leukemia (AML) [1]. According to the SEER database from 2010 to 2017, the 5-year overall survival (OS) in individuals with AML diagnosis over 70 years of age was around 5% [2]. We describe a case of nearly one-year survival in an elderly patient with a very high-risk myelodysplastic syndrome (MDS) that later transformed into AML with supportive therapy only